Achillion fourth quarter revenue is $2 million for three months ended December 31.

, a innovator in the discovery and advancement of small molecule medications to fight the most demanding infectious diseases, reported financial outcomes for the three and twelve months finished December 31 today, 2010. December 31 For the 90 days ended, 2010, the Company reported a net lack of $6.2 million, compared to a net lack of $6.7 million in the three months ended December 31, 2009. For the entire year ended December 31, 2010, the business’s net loss was $25.5 million, compared to a net lack of $25.december 31 9 million for the year ended, 2009.2 million.AMERICA spends more than $2 trillion annually on healthcare. While overall life expectancy has improved, many patients fail to get the most likely treatment. Some get too much care. Others get inadequate. ‘Despite having the priciest healthcare system in the globe, patients are at the mercy of too many mistakes, an excessive amount of miscommunication and an excessive amount of inequity,’ stated Dr. Risa Lavizzo-Mourey, president and CEO of the building blocks. She said the money allows communities to bring together doctors, employers, patients and others to determine which chronic ailments would be targeted. The building blocks shall provide resources and technical expertise. Doctors shall find out about changes they can make to boost care. Patients will understand how to raised manage their conditions, said Lavizzo-Mourey.